European Journal of Cardiovascular Medicine

Background: Uterine fibroid is a common concern  due to associated heavy menstrual bleeding and  anemia negatively affecting women's life. The prevalence of uterine fibroid in India is upto 20-30% in reproductive females. Though surgical treatment still remains the mainstay of the treatment, medical methods had evolved over the years with the advent of many effective oral drugs. Methods: This comparative, interventional study  conducted in the Gynaecological outpatient department of Nil Ratan Sircar Medical College and Hospital, Kolkata from March 2020 to August 2021. This study total of 21 patients in each group i.e. 42 women aged 20-50 years with leiomyoma uterus on USG who were fulfilling the inclusion and exclusion criteria were included in this study. Statistical data were analysed by using Microsoft Excel and SPSS V.20 software. Results: Age of the treated patients ranged between 33 to 50 years and maximum number of patients were in the age group between 41 to 45 years (40.5%). Maximum numbers of patients belonged to lower socioeconomic status; 38.1% and 47.6%. In both groups maximum fibroids were intramural in location; (61.9%) and (71.4%). Maximum number of patients had solitary fibroids (54.8%). Mean age of women in Mifepristone group & Ormeloxifene group were 39.76 ± 3.820 years and 41.48 ± 4.966 years respectively. The baseline mean Hb was 9.46 ± 0.45 gm% and 9.48 ± 0.39 gm% in the mifepristone group & ormeloxifene group respectively. The baseline mean PBAC score was 226.84 ± 28 and 213.16 ± 32.02 in the mifepristone group & ormeloxifene group respectively. The baseline mean fibroid size was 5.91 ± 1.54 cm and 5.38 ± 1.34 cm in the mifepristone group & ormeloxifene group respectively. The baseline mean fibroid volume was 72.43 ± 23.44 cc and 73.19 ± 21.56 cc in the mifepristone group & ormeloxifene group respectively. The baseline mean RI was 0.53 ± 0.16 and 0.58 ± 0.18 in the mifepristone group & ormeloxifene group respectively. The baseline mean ET was 7.03 ± 1.37 mm and 7.9 ± 1.87 mm in the mifepristone group & ormeloxifene group respectively. Conclusions: Mifepristone is more efficacious for the medical management of uterine fibroids as it significantly decreases the uterine fibroid size and volume along with reduction of menstrual blood.